Science Explorer Back to mapMap
Institution · Baxter (Austria)

Most cited papers from Baxter (Austria)

What are the most cited papers from Baxter (Austria)?

The most cited paper from Baxter (Austria) is "PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs" (Peter L. Turecek, Mary J. Bossard, Freddy Schoetens et al., 2016), with 734 citations. Next come "A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1" (521) and "Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study" (440).

Showing 50 of 60 papers. Every paper with more than 119 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs Peter L. Turecek, Mary J. Bossard, Freddy Schoetens et al. · Journal of Pharmaceutical Sciences Open access 29 Jan 2016 734
2 A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1 Gabriela M. Stiegler, Renate Kunert, Martin Purtscher et al. · AIDS Research and Human Retroviruses 10 Dec 2001 521
3 Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study Ester D. de Kleijn, Ronald de Groot, C. Erik Hack et al. · Critical Care Medicine Jun 2003 440
4 The Comparison of the Efficacy and Safety of Intravenous Versus Subcutaneous Immunoglobulin Replacement Therapy Helen M Chapel, Gavin Spickett, Diddi Ericson et al. · Journal of Clinical Immunology Mar 2000 328
5 Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A P. W. COLLINS, Victor S. Blanchette, Kathelijn Fischer et al. · Journal of Thrombosis and Haemostasis Open access 21 Dec 2008 324
6 ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases Michael Rieger · Blood 12 May 2005 316
7 Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II James Alan Tumlin, Raghavan Murugan, Adam M. Deane et al. · Critical Care Medicine Open access 6 Mar 2018 300
8 Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity Silvia Ferrari et al. · Blood 12 Dec 2006 298
9 Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines Perry Barrett, Wolfgang Mundt, Otfried Kistner et al. · Expert Review of Vaccines 27 Apr 2009 286
10 A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture Hartmut J. Ehrlich, Markus Müller, Helen May‐Lin Oh et al. · New England Journal of Medicine Open access 11 Jun 2008 276
11 von Willebrand factor–cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke Bing–Qiao Zhao, Anil Kumar Chauhan, Matthias Canault et al. · Blood Open access 17 Aug 2009 264
12 High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension Diana Bonderman, Peter L. Turecek, Johannes Jakowitsch et al. · Thrombosis and Haemostasis 2003 259
13 Nonneutralizing IgM and IgG antibodies to von Willebrand factor–cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura Friedrich Scheiflinger, Paul Knöbl, Bettina Trattner et al. · Blood 15 Jul 2003 235
14 Binding of disease-associated prion protein to plasminogen Michael Bernhard Fischer, Christiane Roeckl, Petra Parizek et al. · Nature Nov 2000 226
15 Development of a mammalian cell (Vero) derived candidate influenza virus vaccine Otfried Kistner · Vaccine May 1998 223
16 Systemic antithrombotic effects of ADAMTS13 Anil Kumar Chauhan, David G. Motto, Colin B. Lamb et al. · The Journal of Experimental Medicine Open access 13 Mar 2006 222
17 Delineation of Borrelia burgdorferi sensu lato species by multilocus sequence analysis and confirmation of the delineation of Borrelia spielmanii sp. nov. D. Richter, Danièle Postic, Natacha Sertour et al. · INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY Apr 2006 222
18 Activated protein C inhibits lipopolysaccharide‐induced nuclear translocation of nuclear factor κB (NF‐κB) and tumour necrosis factor α (TNF‐α) production in the THP‐1 monocytic cell line B. Douglas White, Marcus Schmidt, Cathriona Murphy et al. · British Journal of Haematology Jul 2000 221
19 Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events Hartmut J. Ehrlich, M. J. HENZL, Edward D. Gomperts · Haemophilia Mar 2002 220
20 Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura Christoph Klaus, Barbara Plaimauer, Jan–Dirk Studt et al. · Blood 24 Feb 2004 219
21 ADAMTS13: a new link between thrombosis and inflammation Anil Kumar Chauhan, Janka Kisucka, Alexander G. Brill et al. · The Journal of Experimental Medicine Open access 11 Aug 2008 218
22 Viral contamination in biologic manufacture and implications for emerging therapies Paul W. Barone et al. · Nature Biotechnology Open access 27 Apr 2020 215
23 Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight Sven Erik Björkman, Myungshin Oh, Gerald E. Spotts et al. · Blood Open access Nov 2011 208
24 IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura Silvia Ferrari, Geert C. Mudde, Michael Rieger et al. · Journal of Thrombosis and Haemostasis Open access 11 Aug 2009 201
25 Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients Shawn F. J. Whelan, Christoph J. Hofbauer, Frank Michael Horling et al. · Blood 14 Dec 2012 186
26 Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens Peter W. Collins, Sven Erik Björkman, Kathelijn Fischer et al. · Journal of Thrombosis and Haemostasis Open access 23 Nov 2009 186
27 New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development Karin Kurnik, Christoph Bidlingmaier, Werner Engl et al. · Haemophilia 30 Oct 2009 178
28 WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer Peter Wend, Stephanie Runke, Korinna Wend et al. · EMBO Molecular Medicine Open access 11 Jan 2013 176
29 Efficacy and safety of OBI ‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A Rebecca Kruse‐Jarres, Jean St‐Louis, A. Greist et al. · Haemophilia Open access 27 Jan 2015 175
30 FEIBA®: mode of action Peter L. Turecek, Katalin Váradi, Herbert Gritsch et al. · Haemophilia Sep 2004 170
31 Low ADAMTS13 activity is associated with an increased risk of ischemic stroke Michelle Sonneveld, Moniek P.M. de Maat, Marileen L.P. Portegies et al. · Blood 28 Oct 2015 169
32 A survey of adherence to haemophilia therapy in six European countries: results and recommendations Philippe de Moerloose, W. Urbancik, H. Marijke van den Berg et al. · Haemophilia Open access 5 Aug 2008 168
33 The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know? Christian Lubich, Peter Allacher, Maurus de la Rosa et al. · Pharmaceutical Research 7 Jun 2016 165
34 Fibrin–Polyurethane Composites for Articular Cartilage Tissue Engineering: A Preliminary Analysis Cynthia R. Lee, Sibylle Grad, Katarzyna Górna et al. · Tissue Engineering Sep 2005 161
35 Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience Y. Benhamou et al. · Haematologica Open access 11 May 2012 159
36 Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin Jan–Dirk Studt, Johanna A. Kremer Hovinga, Gerhard Antoine et al. · Blood Open access 14 Sep 2004 159
37 Comprehensive glyco‐proteomic analysis of human α1‐antitrypsin and its charge isoforms Daniel Kolarich, Alfred Weber, Peter L. Turecek et al. · PROTEOMICS 18 Apr 2006 155
38 Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays Lisa Weidner, Simon Gänsdorfer, Stephan Unterweger et al. · Journal of Clinical Virology Open access 6 Jul 2020 153
39 Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy Michèle Cavo, Elena Zamagni, Claudia Cellini et al. · Blood Open access 28 Aug 2002 152
40 Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency Richard L. Wasserman, Isaac Melamed, Mark R. Stein et al. · Journal of Allergy and Clinical Immunology Open access 28 Jul 2012 151
41 ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense Thomas P. C. Monath, Joseph R. Caldwell, Wolfgang Mundt et al. · International Journal of Infectious Diseases Open access Oct 2004 148
42 Emerging trends in plasma‐free manufacturing of recombinant protein therapeutics expressed in mammalian cells Leopold Grillberger, Thomas R. Kreil, Sonia Ben Nasr et al. · Biotechnology Journal Open access Feb 2009 143
43 Monitoring the bioavailability of FEIBA with a thrombin generation assay Katalin Váradi, Claude Négrier, Erik E. Berntorp et al. · Journal of Thrombosis and Haemostasis Open access Nov 2003 142
44 Comparison of regenerated and non-regenerated oxidized cellulose hemostatic agents Kevin M. Lewis, Daniel Spazierer, Manfred Urban et al. · European surgery. Supplement/European surgery Open access 3 Jul 2013 140
45 Taking immunogenicity assessment of therapeutic proteins to the next level Isabel Büttel et al. · Biologicals 25 Feb 2011 140
46 Complement Factor H Mutation in Familial Thrombotic Thrombocytopenic Purpura with ADAMTS13 Deficiency and Renal Involvement Marina Noris, Sara Bucchioni, Miriam Galbusera et al. · Journal of the American Society of Nephrology 30 Mar 2005 138
47 Non‐genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report Jan Astermark, Carmen Altisent, Angelika Bátorová et al. · Haemophilia Open access 14 Apr 2010 138
48 Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies Barbara Plaimauer, Johanna A. Kremer Hovinga, Claudia Juno et al. · Journal of Thrombosis and Haemostasis Open access 5 Feb 2011 130
49 Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial Pier Mannuccio Mannucci, Christine L. Kempton, Carolyn M. Millar et al. · Blood Open access 18 Jun 2013 129
50 Improvement of bioprocess monitoring: development of novel concepts Franz Clementschitsch, Karl Bayer · Microbial Cell Factories Open access 22 May 2006 129

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.